NPPA Caps Retail Prices Of 2 Formulations

Mumbai : The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 2 formulations under Drugs Prices Control Order (DPCO) – 2013 based on the decision of 86th authority meeting dated April 28, 2021.

The formulations are budesonide tablet and dexamethasone tablet.

The manufacturer of these formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified. The manufacturer may add goods and services tax only if they have paid actually or it is payable to the government on the retail price as prescribed by NPPA.

The retail price for a pack of these formulations shall be arrived at by the concerned manufacturer in accordance with the retail price specified as per provisions contained in paragraph 11 of the DPCO, 2013.

The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller (SDC) and dealers.

As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

The retail price fixed is applicable only to the individual manufacturer/marketer as specified i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO 2013.

In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

  • Related Posts

    India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

    The report emphasizes that absolute R&D spending remains modest and identifies expanding investment in advanced biologics and AI-driven drug discovery as the “largest opportunity” for bridging the innovation divide. Recent…

    India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

    Early-stage activity drove the month, accounting for 73.6 per cent of total investments, while seed-stage rounds contributed the remaining 26.4 per cent. India’s pharma and healthcare funding for November 2025…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

    India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

    India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

    India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

    India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

    India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

    Novo Nordisk gears up for December Ozempic launch

    Novo Nordisk gears up for December Ozempic launch

    Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

    Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

    Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit

    Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit